scholarly journals Prognostic and clinicopathological significance of Beclin-1 in non-small-cell lung cancer: a meta-analysis

2018 ◽  
Vol Volume 11 ◽  
pp. 4167-4175 ◽  
Author(s):  
Tianliang Zheng ◽  
Deping Li ◽  
Zhanfeng He ◽  
Shuaibing Feng ◽  
Song Zhao
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Meta Analysis ◽  
Small Cell ◽  
Beclin 1 ◽  
Small Cell Lung ◽  
Clinicopathological Significance

scholarly journals Clinicopathological significance of CHFR methylation in non-small cell lung cancer: a systematic review and meta-analysis

Oncotarget ◽  
2017 ◽  
Vol 8 (65) ◽  
pp. 109732-109739
Author(s):  
Chen Wang ◽  
Wenxia Ma ◽  
Rong Wei ◽  
Xiaoqin Zhang ◽  
Ningning Shen ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Systematic Review ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Meta Analysis ◽  
Small Cell ◽  
Small Cell Lung ◽  
Clinicopathological Significance

scholarly journals Clinicopathological significance of DAPK gene promoter hypermethylation in non-small cell lung cancer: A meta-analysis

2021 ◽  
pp. 172460082110675
Author(s):  
Zhimao Chen ◽  
Yu Fan ◽  
Xiangzheng Liu ◽  
Xueqian Shang ◽  
Kang Qi ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Meta Analysis ◽  
Gene Promoter ◽  
Promoter Hypermethylation ◽  
Small Cell ◽  
Cochrane Library ◽  
Small Cell Lung ◽  
Clinicopathological Significance

Background Death-associated protein kinase (DAPK) has a strong function of tumor suppression involving apoptosis regulation, autophagy, and metastasis inhibition. Hypermethylation of CpG islands in DAPK gene promoter region is one of the important ways to inactivate this tumor suppressor gene, which might promote lung carcinogenesis. However, the clinicopathological significance of the DAPK promoter hypermethylation in lung cancer remains unclear. In this study, we performed a meta-analysis trying to estimate the clinicopathological significance of DAPK promoter hypermethylation in non-small cell lung cancer (NSCLC). Methods A detailed literature search for publications relevant to DAPK gene promoter methylation and NSCLC was made in PubMed, Embase, Cochrane Library, Web of Science, China National Knowledge Infrastructure, CSTJ, Wanfang databases, and SinoMed (CBM). The random-effects model and fixed-effects model were utilized to pool the relative ratio based on the heterogeneity test in the meta-analysis. Results A total of 41 studies with 3348 patients were included. The frequency of DAPK methylation was significantly higher in NSCLC than in non-malignant control (odds ratio (OR) = 6.88, 95% confidence interval (CI):  4.17–11.35, P < 0.00001). The pooled results also showed that DAPK gene promoter hypermethylation was significantly associated with poor prognosis for overall survival in patients with NSCLC (hazard ratio: 1.23, 95% CI:1.01–1.52, P = 0.04). Moreover, DAPK gene promoter hypermethylation was significantly associated with squamous cell carcinoma (OR: 1.25, 95% CI: 1.01–1.54, P = 0.04) and smoking behavior (OR: 1.42, 95% CI: 1.04–1.93, P = 0.03) but not with TNM stage, tumor differentiation, age, or gender. Conclusion DAPK promoter hypermethylation might be a candidate diagnostic and prognostic tumor marker for NSCLC.

Sign in / Sign up

Export Citation Format

Share Document